Clinical evidence supports GLP-1/GIP agonists for body composition changes, and adding sermorelin's anabolic properties may enhance this outcome
Stomach paralysis is a more general, non-medical term
Yes, switching is common and usually done for cost, access, or convenience, but your doctor sets the timing and dose
For the best results, we recommend that you stay on your treatment long-term depending on your healthcare professionals recommendation and your specific weight-loss goals
Read our full statement on the growing bipartisan momentum for market-based solutions to boost competition and lower drug prices: To view or add a comment, sign in Novo Nordisk has sued Eli Lilly, alleging its advertising for Zepbound and Mounjaro misleads consumers by comparing the highest doses of Lilly's drugs with lower, outdated doses of Wegovy and Ozempic, escalating the rivalry in the rapidly growing GLP-1 market
Why Choose Stem Cell & PRP Institute of L.A